Remdesivir, which is the current most suited therapeutic drug for COVID-19 along with α-hederin, Thymohydroquinone and Thymoquinone were further explored more for their mode of action (Figure 4(a–c)). Since the initial diagnosis of COVID-19 is compromised immunity and it is always associated with inflammation and oxidative stress therefore it is suggested that N. sativa bioactive constituents can be very useful for boosting our immunity and helping patients to overcome the symptoms of COVID-19. While Remdesivir was observed to be targeting proteins involved in growth and proliferation (Figure 4(a)), α-hederin was observed to be engaged in regulation of blood pressure, regulation of cell communication, regulation of vascular processes, negative regulation of cell death, response to stress and immune effector processes. The genes identified for regulating immune response via α-hederin are ACE2, F2, SRC etc (Figure 4(b)). Thymohydroquinone was observed to be targeting proteins involved in response to oxidative stress, negative regulation of cell death, regulation of blood pressure, positive regulation of kinase activity, regulation of immune response etc. Regulation of immune response by thymohydroquinone was through genes like HSP90AA1, PRKCA, VEGFA, ADORA1 etc. (Figure 4(c)) and Thymoquinone was seen to be targeting kinases, heat shock proteins and oxidoreductases (Figure 4(d)).